Showing results (1161-1170 of 1,190) with videos related to

Sort By:
Pageof 119
Cancers|October 13, 2021
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 TrialEva-Maria Klein, Diana Tichy, Hans J Salwender, et al.
Acta Neuropathologica|April 23, 2013
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's diseaseJens Wagner, Sergey Ryazanov, Andrei Leonov, et al.
Blood Cancer Journal|January 8, 2021
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myelomaMarc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, et al.
Frontiers in Psychiatry|March 21, 2022
Concept of the Munich/Augsburg Consortium Precision in Mental Health for the German Center of Mental HealthPeter Falkai, Nikolaos Koutsouleris, Katja Bertsch, et al.
Nature Medicine|June 25, 2026
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trialMarc S Raab, Niels Weinhold, K Martin Kortüm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple MyelomaMartin F Kaiser, Pieter Sonneveld, David A Cairns, et al.
Leukemia|December 7, 2023
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patientsElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
JAMA Neurology|September 4, 2019
Prehospital Stroke Management Optimized by Use of Clinical Scoring vs Mobile Stroke Unit for Triage of Patients With Stroke: A Randomized Clinical TrialStefan A Helwig, Andreas Ragoschke-Schumm, Lenka Schwindling, et al.
Haematologica|January 2, 2008
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myelomaHenk M Lokhorst, Ingo Schmidt-Wolf, Pieter Sonneveld, et al.
Haematologica|September 3, 2013
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trialChristof Scheid, Pieter Sonneveld, Ingo G H Schmidt-Wolf, et al.
Pageof 119